score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Investigate Actionability - High	Preclinical			Copy Number	CCNE1	Amplification							Investigate Actionability - High	Bortezomib	Targeted therapy	Sensitivity to Bortezomib was observed in ovarian cancer cell lines.	"Etemadmoghadam, Dariush, et al. ""Synthetic lethality between CCNE1 amplification and loss of BRCA1."" Proceedings of the National Academy of Sciences 110.48 (2013): 19489-19494."	https://doi.org/10.1073/pnas.1314302110																CCNE1 Amplification		112		
Investigate Actionability - High		Clinical evidence	Clinical evidence	Somatic Variant	TP53	Missense	p.R248W												Investigate Actionability - Low	Lenalidomide	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability - High	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248W (Missense)		112		
Investigate Actionability - Low	FDA-Approved			Rearrangement	ABL1	Fusion	NUP214-ABL1						Investigate Actionability - Low	Bosutinib	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for adult patients with chronic, accelerated, or blast phase Philidelphia chromosome-positive (Ph+) CML with resistance or intolernace to prior therapy.	Bosulif [package insert]. New York, NY: Pfizer Inc.; 2012.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203341lbl.pdf																NUP214-ABL1 Fusion		112		
